The recent clinical setback in a Phase 2b trial of a competing product with a similar indication but a different mechanism of action, presents Sol-Gel with the opportunity to be a durable market leader in Gorlin syndrome, if our own Phase III program succeeds. Seri Levy continued, “We are on track with our plans to initiate the pivotal Phase 3 trial for SGT-610 (patidegib), our recently acquired, Breakthrough-designated, Orphan Drug candidate with a market potential of over $300 million for the prevention of basal cell carcinoma in subjects having Gorlin syndrome, in late 2023. may be approaching a plateau due to the genericization of both the acne and rosacea markets.”ĭr.
![dr olay dorsal column stimulator trial dr olay dorsal column stimulator trial](https://i.ytimg.com/vi/C1e84KmcjRs/maxresdefault.jpg)
“Based on current discussions we expect more international licenses will follow in the future, while coverage and demand for both products in the U.S. We are delighted to partner these first products developed by Sol-Gel with Searchlight Pharma in Canada, a leading commercial territory, over a fifteen-year term that is renewable for subsequent five-year periods,” stated Alon Seri Levy, Ph.D., Chief Executive Officer of Sol-Gel. “We were pleased to announce another TWYNEO and EPSOLAY partnership during the quarter which generated non-dilutive revenue for our shareholders. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, EPSOLAY and TWYNEO, today announced financial results for the second quarter ended Jand provided a corporate update. 10, 2023 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd.
![dr olay dorsal column stimulator trial dr olay dorsal column stimulator trial](https://i.ytimg.com/vi/ctTSivqcgoY/maxresdefault.jpg)
Sol-Gel has cash runway into the second half of 2025 Sol-Gel’s recently announced agreement with Searchlight Pharma will provide up to $11 million in upfront payments and regulatory and sales milestones for both TWYNEO® and EPSOLAY®, combined, plus additional royalties ranging from low double-digits to high-teens Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023